AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25708818 — intervention group
Group type: EXPERIMENTAL
Intervention: Total facial nerve decompression (surgery group)
Number of subjects: 15
Study 25708818 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone treatment (control group)
Number of subjects: 15
Study 22948805 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocervical curettage (ECC)
Number of subjects: 208
Study 22948805 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocervical brushing (EB)
Number of subjects: 208
Study 20110339 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 20
Study 20110339 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 20
Study 18205045 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-year disease-free survival (DFS)
Number of subjects: 0
Study 18205045 — intervention group
Group type: EXPERIMENTAL
Intervention: DFS at 2 or 3 years
Number of subjects: 0
Study 15665717 — intervention group
Group type: EXPERIMENTAL
Intervention: DT-pertussis toxoid
Number of subjects: 0
Study 15665717 — intervention group
Group type: COMPARATOR
Intervention: DT
Number of subjects: 0
Study 14500176 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine with sevoflurane anesthesia (Group 1)
Number of subjects: 35
Study 14500176 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine with sevoflurane anesthesia (Group 2)
Number of subjects: 35
Study 14500176 — intervention group
Group type: COMPARATOR
Intervention: Both groups (0.5% and 1% lidocaine)
Number of subjects: 35
Study 10383546 — intervention group
Group type: EXPERIMENTAL
Intervention: WAG 994 1 mg
Number of subjects: 122
Study 10383546 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 122
Study 10383546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 8558223 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (IFN alpha-2b) administered at 20 MU/m2/d intravenously for 1 month and 10 MU/m2 three times per week subcutaneously for 48 weeks
Number of subjects: 287
Study 8558223 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (IFN alpha-2b)
Number of subjects: 287
Study 8558223 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 287
Study 1828765 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol (20 micrograms)
Number of subjects: 20
Study 1828765 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (200 micrograms)
Number of subjects: 20
Study 1828765 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol
Number of subjects: 20
Study 1828765 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 20
Study 1828765 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 20
Study 6348227 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of amikacin 7.5 mg/kg intramuscularly
Number of subjects: 54
Study 6348227 — intervention group
Group type: COMPARATOR
Intervention: Sulfisoxazole 150 mg/kg/day orally for 10 days
Number of subjects: 54
Study 30586730 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 50 mg
Number of subjects: 10061
Study 30586730 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Number of subjects: 10061
Study 30586730 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 300 mg
Number of subjects: 10061
Study 30586730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10061
Study 29589490 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline factors associated with lower physical HRQL
Number of subjects: 0
Study 29589490 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline factors associated with mental HRQL, hip function, and health utility
Number of subjects: 0
Study 25956926 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physical activity and fall prevention intervention enhanced with health coaching and pedometers
Number of subjects: 130
Study 25956926 — intervention group
Group type: COMPARATOR
Intervention: Advice brochure (control group)
Number of subjects: 130
Study 24114811 — intervention group
Group type: EXPERIMENTAL
Intervention: AG013 (oral rinse containing recombinant Lactococcus lactis secreting hTFF1)
Number of subjects: 25
Study 24114811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 24114811 — intervention group
Group type: EXPERIMENTAL
Intervention: AG013
Number of subjects: 25
Study 24114811 — intervention group
Group type: COMPARATOR
Intervention: AG013 or placebo
Number of subjects: 25
Study 21671743 — intervention group
Group type: COMPARATOR
Intervention: Neural correlates of autobiographical memory retrieval
Number of subjects: 0
Study 21671743 — intervention group
Group type: COMPARATOR
Intervention: Neural correlates of episodic memory retrieval
Number of subjects: 0
Study 21671743 — intervention group
Group type: COMPARATOR
Intervention: Neural correlates of semantic memory retrieval
Number of subjects: 0
Study 21671743 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 19349543 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin (IP) - irinotecan 60 mg/m² on days 1, 8, and 15; cisplatin 60 mg/m² day 1, every 4 weeks
Number of subjects: 651
Study 19349543 — intervention group
Group type: COMPARATOR
Intervention: Etoposide plus cisplatin (EP) - etoposide 100 mg/m² on days 1 through 3; cisplatin 80 mg/m² day 1, every 3 weeks
Number of subjects: 651
Study 17250718 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy young subjects
Number of subjects: 90
Study 17250718 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy old subjects
Number of subjects: 90
Study 17250718 — intervention group
Group type: COMPARATOR
Intervention: Old subjects with vascular risk factors
Number of subjects: 90
Study 17250718 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy young and old subjects
Number of subjects: 90
Study 15479311 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled propofol infusion
Number of subjects: 50
Study 15479311 — intervention group
Group type: COMPARATOR
Intervention: Manual propofol infusion
Number of subjects: 50
Study 11528490 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dose of iodized oil, containing 540 mg I
Number of subjects: 197
Study 11528490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 11367648 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinmaitong (XMT) capsule
Number of subjects: 38
Study 11367648 — intervention group
Group type: COMPARATOR
Intervention: Conventional western medical therapy
Number of subjects: 38
Study 7583724 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical CT with monophasic injections of contrast agent at 3 mL/second
Number of subjects: 166
Study 7583724 — intervention group
Group type: COMPARATOR
Intervention: Conventional CT with biphasic injections at 2 and 0.7 mL/second
Number of subjects: 166
Study 1976782 — intervention group
Group type: EXPERIMENTAL
Intervention: (+/‐)‐propranolol base (0.108 mg kg‐1 of ideal body weight)
Number of subjects: 6
Study 1976782 — intervention group
Group type: EXPERIMENTAL
Intervention: (+/‐)‐sotalol base (1.06 mg kg‐1 of ideal body weight)
Number of subjects: 6
Study 1976782 — intervention group
Group type: COMPARATOR
Intervention: Non-obese control subjects
Number of subjects: 6
Study 359625 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous terbutaline
Number of subjects: 0
Study 359625 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline (5 mg)
Number of subjects: 0
Study 30970057 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosemary-based toothpaste (Group A)
Number of subjects: 110
Study 30970057 — intervention group
Group type: COMPARATOR
Intervention: Conventional toothpaste (Group B)
Number of subjects: 110
Study 26446930 — intervention group
Group type: EXPERIMENTAL
Intervention: He-Ne laser irradiation (632.8 nm, 10 mw, 6 j/cm² density)
Number of subjects: 30
Study 26446930 — intervention group
Group type: COMPARATOR
Intervention: Placebo (device powered off)
Number of subjects: 30
Study 26446930 — intervention group
Group type: EXPERIMENTAL
Intervention: He-Ne laser irradiation
Number of subjects: 30
Study 26446930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22183134 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxy-vitamin D (25-OH-VitD) levels in DMT2 subjects
Number of subjects: 266
Study 22183134 — intervention group
Group type: COMPARATOR
Intervention: 25-hydroxy-vitamin D (25-OH-VitD) levels in control group
Number of subjects: 266
Study 22183134 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxy-vitamin D (25-OH-VitD) levels in entire population
Number of subjects: 266
Study 21623389 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined infusion of propofol and remifentanil
Number of subjects: 100
Study 21623389 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine jelly
Number of subjects: 100
Study 19936371 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 18
Study 19936371 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 18
Study 17013734 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipedal standing balance exercise (1 min, 3 times per day)
Number of subjects: 553
Study 17013734 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 553
Study 17013734 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipedal standing balance exercise
Number of subjects: 553
Study 12724021 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) with ten different estrogen or estrogen‐progestin molecules, regimens and routes of administration
Number of subjects: 186
Study 12724021 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal HRT
Number of subjects: 186
Study 12724021 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT with progestin molecules (except for 19‐nor derivatives) added to transdermal estradiol administration
Number of subjects: 186
Study 12724021 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA levels
Number of subjects: 186
Study 11061055 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 351
Study 11061055 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 351
Study 11061055 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amlodipine and atenolol
Number of subjects: 351
Study 9011896 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 39
Study 9011896 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 39
Study 1424937 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized decision tree or clinical algorithm for treatment
Number of subjects: 0
Study 1424937 — intervention group
Group type: EXPERIMENTAL
Intervention: Supranormal oxygen transport values
Number of subjects: 0
Study 1424937 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac index (CI), oxygen delivery (DO2), and oxygen consumption (VO2)
Number of subjects: 0
Study 1424937 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized algorithms and individualized decision analysis
Number of subjects: 0
Study 3909587 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 165
Study 3909587 — intervention group
Group type: COMPARATOR
Intervention: Conventional immunosuppressive therapy (azathioprine and steroids)
Number of subjects: 165
Study 3909587 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A combined with steroids
Number of subjects: 165
Study 30393955 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy targeting LDL cholesterol <1.81 mmol/L
Number of subjects: 1909
Study 30393955 — intervention group
Group type: COMPARATOR
Intervention: Standard statin therapy targeting LDL cholesterol ≥2.59 to <3.10 mmol/L
Number of subjects: 1909
Study 29788920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (COPE study)
Number of subjects: 10
Study 29788920 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 27309494 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental arithmetic task (high stress and anxiety)
Number of subjects: 36
Study 27309494 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no stress and anxiety)
Number of subjects: 36
Study 25211775 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (details not specified)
Number of subjects: 1260
Study 25211775 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 1260
Study 21538074 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliance therapy
Number of subjects: 103
Study 21538074 — intervention group
Group type: COMPARATOR
Intervention: CPAP therapy
Number of subjects: 103
Study 21538074 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 103
Study 21538074 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term oral appliance use
Number of subjects: 103
Study 20129008 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day educational seminar and monthly group guidance for 6 months
Number of subjects: 145
Study 20129008 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 145
Study 17369710 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Protein Index (BPI) measured by multifrequency bioelectrical impedance analysis in HD patients
Number of subjects: 448
Study 17369710 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Protein Index (BPI) measured by multifrequency bioelectrical impedance analysis in PD patients
Number of subjects: 448
Study 17369710 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Protein Index (BPI) in women HD patients
Number of subjects: 448
Study 17369710 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Protein Index (BPI) in women PD patients
Number of subjects: 448
Study 17369710 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status classification based on BPI in HD patients
Number of subjects: 448
Study 17369710 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of BPI with serum albumin and transferrin concentrations
Number of subjects: 448
Study 17369710 — intervention group
Group type: EXPERIMENTAL
Intervention: BPI in relation to dialysis history
Number of subjects: 448
Study 15725144 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled prostacyclin
Number of subjects: 58
Study 15725144 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 58
Study 15725144 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside (i.v.)
Number of subjects: 58
Study 12059059 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS) screening
Number of subjects: 13288
Study 12059059 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of FS and faecal occult blood test (FOBT)
Number of subjects: 13288
Study 12059059 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall attendance rate
Number of subjects: 13288
Study 12059059 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening in Telemark
Number of subjects: 13288
Study 12059059 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening in Oslo
Number of subjects: 13288
Study 9864836 — intervention group
Group type: COMPARATOR
Intervention: TNFR55-IgG1 (2.5-100 mg/month, given i.v., cumulative doses from 40-940 mg)
Number of subjects: 80
Study 8589768 — intervention group
Group type: EXPERIMENTAL
Intervention: casein-soy VLED (96 g protein, 1.7 MJ/d)
Number of subjects: 6
Study 8589768 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrolyzed collagen VLED (tryptophan- and methionine-supplemented)
Number of subjects: 6
Study 8589768 — intervention group
Group type: EXPERIMENTAL
Intervention: both VLEDs
Number of subjects: 6
Study 8589768 — intervention group
Group type: COMPARATOR
Intervention: casein-soy VLED
Number of subjects: 6
Study 8589768 — intervention group
Group type: COMPARATOR
Intervention: hydrolyzed collagen VLED
Number of subjects: 6
Study 2184790 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician recognition of depression (defined by chart notation or prescription of antidepressants)
Number of subjects: 265
Study 2184790 — intervention group
Group type: COMPARATOR
Intervention: Physician misdiagnosis of depression
Number of subjects: 265
Study 2184790 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report depression scales
Number of subjects: 265
Study 6965176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive family therapy
Number of subjects: 11
Study 31063856 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle focused text messaging intervention
Number of subjects: 229
Study 31063856 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 229
Study 29166854 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's lactate 10 mL containing dezocine 0.1 mg/kg (Group D)
Number of subjects: 100
Study 29166854 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate 10 mL (Group C)
Number of subjects: 100
Study 26076191 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide s.c. depot A 10, 20 or 30 mg, B 30 mg, C 10, 20 or 30 mg
Number of subjects: 122
Study 26076191 — intervention group
Group type: COMPARATOR
Intervention: Octreotide LAR 30 mg
Number of subjects: 122
Study 23591188 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS) imaging
Number of subjects: 171
Study 23591188 — intervention group
Group type: COMPARATOR
Intervention: Multislice computed tomography (MS-CT) angiography
Number of subjects: 171
Study 20953864 — intervention group
Group type: EXPERIMENTAL
Intervention: Subvastus approach
Number of subjects: 40
Study 20953864 — intervention group
Group type: COMPARATOR
Intervention: Parapatellar approach
Number of subjects: 40
Study 19266107 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavored supplement (Group 1)
Number of subjects: 125
Study 19266107 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-flavored (neutral) supplement (Group 2)
Number of subjects: 125
Study 19266107 — intervention group
Group type: EXPERIMENTAL
Intervention: Kitchen foods as supplements (Group 3)
Number of subjects: 125
Study 19266107 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 125
Study 19266107 — intervention group
Group type: COMPARATOR
Intervention: Commercial supplemented groups (G1 and G2)
Number of subjects: 125
Study 19266107 — intervention group
Group type: COMPARATOR
Intervention: Energy requirements fulfillment
Number of subjects: 125
Study 17056206 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication coaching plus voucher reinforcement for opening electronic medication caps on time
Number of subjects: 66
Study 17056206 — intervention group
Group type: COMPARATOR
Intervention: Medication coaching sessions every other week (comparison group)
Number of subjects: 66
Study 15377466 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF 5 micro g/kg/day (group A)
Number of subjects: 77
Study 15377466 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF 10 micro g/kg/day (group B)
Number of subjects: 77
Study 11704164 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient group (Foley catheter placement, discharged home)
Number of subjects: 111
Study 11704164 — intervention group
Group type: COMPARATOR
Intervention: Inpatient group (Foley catheter placement, admitted to labor and delivery)
Number of subjects: 111
Study 9863077 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of artesunate tablet over 3 days
Number of subjects: 90
Study 9863077 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of artesunate tablet over 5 days
Number of subjects: 90
Study 9863077 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg of artesunate tablet over 7 days
Number of subjects: 90
Study 7910560 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin-28 (S-28) infusion
Number of subjects: 0
Study 7910560 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin-14 (S-14) infusion
Number of subjects: 0
Study 3302248 — intervention group
Group type: EXPERIMENTAL
Intervention: d,alpha-tocopherol (400 IU daily for three cycles)
Number of subjects: 46
Study 3302248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 30076365 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraslow neurofeedback (ISF-NF)
Number of subjects: 21
Study 30076365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 28688961 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive familiarization
Number of subjects: 45
Study 28688961 — intervention group
Group type: EXPERIMENTAL
Intervention: Motionless familiarization
Number of subjects: 45
Study 28688961 — intervention group
Group type: EXPERIMENTAL
Intervention: Active sleep duration
Number of subjects: 45
Study 26406087 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse wave analysis during VDT operation
Number of subjects: 30
Study 23769235 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir plus raltegravir
Number of subjects: 558
Study 23769235 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted lopinavir plus two or three NtRTIs (control group)
Number of subjects: 558
Study 23769235 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 558
Study 23769235 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir group
Number of subjects: 558
Study 20940639 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 minute rest interval
Number of subjects: 17
Study 20940639 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 minute rest interval
Number of subjects: 17
Study 20940639 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 17
Study 18443980 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medication (typical or atypical)
Number of subjects: 0
Study 18443980 — intervention group
Group type: COMPARATOR
Intervention: Other interventions
Number of subjects: 0
Study 15681940 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 U/kg recombinant human antithrombin (rhAT)
Number of subjects: 54
Study 15681940 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 54
Study 14555373 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiredness
Number of subjects: 1155